Ionis Pharmaceuticals INC (IONS) — 10-Q Filings

10-Q Filings (6)

• Ionis Revenue Soars 55% on New Drug Launches, Narrows Net Loss — Oct 29, 2025 Risk: medium
  Ionis Pharmaceuticals Inc. reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $740.38 million, up from $478
• Ionis's Revenue Jumps 17%, But Net Loss Widens to $55.3M — Jul 30, 2025 Risk: medium
  Ionis Pharmaceuticals Inc. reported a significant increase in revenue for the quarter ended June 30, 2025, reaching $210.5 million, up from $180.2 million in th
• Ionis Pharmaceuticals Files Q1 2025 10-Q — Apr 30, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported revenue from various sources including Research and Developm
• Ionis Pharma Q3 Revenue Declines — Nov 6, 2024 Risk: medium
  Ionis Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported collaborative agreement revenue of $190.6 million for
• Ionis Pharmaceuticals Q2 2024: $300.6M Revenue, $1.4B Cash — Aug 1, 2024 Risk: medium
  Ionis Pharmaceuticals Inc. reported its Q2 2024 results, with total revenue for the six months ended June 30, 2024, reaching $300.6 million. The company's cash,
• Ionis Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
  IONIS PHARMACEUTICALS INC (IONS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Ionis Pharmaceuticals Inc. filed a 10-Q report for the period endi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX